Date: 2013-11-21
Type of information: Initiation of the trial
phase: 1
Announcement: initiation of the trial
Company: Amgen (USA - CA)
Product: AMG 232
Action
mechanism: MDM2 inhibitor. AMG 232 is an orally available, piperidinone inhibitor of MDM2 (murine double minute 2). It binds to MDM2 protein and prevents its binding to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this MDM2-p53 interaction, the transcriptional activity of p53 is restored. This leads to p53-mediated induction of tumor cell apoptosis.
Disease: acute myeloid leukemia
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: This phase 1b study is evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 232 alone and in combination with trametinib in subjects with acute myeloid leukemia. (NCT02016729)
Latest
news: * On November 21, 2013, a Phase I trial sponsored by Amgen was published on the NIH website ClinicalTrials.gov for AMG 232 and is currently recruiting participants.
